Talabostat: Preliminary Phase II data

Preliminary data from an open-label, U.S. Phase II trial in 20 evaluable patients showed

Read the full 145 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE